The Colorado Infectious Diseases Clinical Trials Unit (IDCTU) is actively enrolling participants in clinical trials focusing on improving the management of HIV and its comorbidities, developing a cure for HIV; and innovative treatments for Hepatitis B, opportunistic infections and emerging infectious diseases. 

Please click here for a list of our currently enrolling ACTG Clinical Trials



A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People ≥ 16 Years of Age Who Have Sex With Male Partners and Are at Risk for HIV Infection

The goal of this clinical study is to test how well the study drug, lenacapavir (LEN), works in reducing the risk of HIV. 

Requirements to Enter Study: 

• Be at least 16 years of age.

• Not have had an HIV test in the past 3 months.

• No oral PrEP in the past 12 weeks or any prior use of long-acting systemic PrEP.

• Be a cisgender man, transgender or gender nonbinary individual who has receptive anal sex. - 

Gilead Purpose 2 Website -

If you are interested in participating in or learning more about our clinical trials please contact

Vanessa Sutton, FNP-BC - 303-724-0712 or 

Joanna Nowakowski, FNP-BC - 303-724-0831

ACTG AIDS Clinical Trials Group

Contact Us

Vanessa Sutton, FNP-BC

Ph: 303-724-0712

Joanna Nowakowski, FNP-BC

Ph: 303-724-0831